Activity of CuDIPS against mammary cancer in C3H HeNCR mice.
A copper complex with superoxide dismutase mimetic activity, Cu(II)2 (3,5-diisopropylsalicylate)4 (CuDIPS), was tested for activity against mammary cancer in female C3H/HeNCR mice. Initiation of treatment at 20 or at 30 weeks of age had a limited beneficial effect on survival rates. Further, a small, but not statistically significant, difference in tumorigenesis was observed in comparisons between experimental and control groups of animals. Implications of these findings are discussed.
Crispens
C G
CG
Department of Biology, University of Alabama, Birmingham 35294.
Sorenson
J R
JR
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004354:Drug Screening Assays, Antitumor; D005260:Female; D015994:Incidence; D007279:Injections, Subcutaneous; D015674:Mammary Neoplasms, Animal / Q000188:drug therapy* / Q000401:mortality; D051379:Mice; D008809:Mice, Inbred C3H; D012459:Salicylates / Q000627:therapeutic use*; D016019:Survival Analysis
D000970:Antineoplastic Agents; D012459:Salicylates; C030865:copper bis(3,5-diisopropylsalicylate)